IMMUNO-ONCOLOGY INSIGHTS

Enhancing preclinical predictivity

Guest Editor:
Christian Schmees at University of Tuebingen
Christian Schmees
at University of Tuebingen
Christian Schmees is heading the Tumor Biology group at the Natural and Medical Sciences Institute (NMI) at the University of Tuebingen, Germany. He received his undergraduate degree in biochemistry from Tuebingen University in 2002. Since 2006 he holds a PhD (with highest honors) in cancer immunology from the Technical University of Munich, Germany. His thesis resulted in the identification of gamma-glutamyl-transpeptidase as the major factor for T cell specific immune evasion of the tumorigenic bacterium Helicobacter pylori. As a post-doc he joined the laboratories of Carl-Henrik Heldin at the Ludwig Institute for Cancer Research (LICR) in Uppsala, Sweden (2006-2010) and Philippe Bastiaens at the Max-Planck Institute of Molecular Physiology in Dortmund, Germany (2010-2011). He received fellowships from the German Research Foundation and the LICR to support his research on differential regulation of intracellular PDGF α- and β-receptor trafficking in cancer cells. In 2011 he joined the Natural and Medical Sciences Institute at the University of Tuebingen (NMI) as a senior scientist in tumor biology and was appointed Head of Tumor Biology in 2014. Ongoing projects in his group are focusing on the development of clinically relevant cellular model systems for drug development and target validation in translational oncology. These approaches are combined with gene editing and silencing technologies as well as protein profiling and immunophenotyping platforms for mode-of-action analyses of different compound classes. Dr. Schmees is member of the Association for Cancer Immunotherapy (CIMT).
July 2021

  • Translational R&D insights for the allogeneic CAR T cell therapy field and beyond

    B Sasu
    Barbra Sasu
    Chief Scientific Officer, Allogene
    Barbra Sasu, PhD, is the Chief Scientific Officer of Allogene. Barbra joined Allogene as Chief Scientific Officer in April 2018 when the company acquired the allogeneic cell therapy assets from Pfizer. Barbra received a PhD from the Paterson Institute for Cancer Research in Manchester, UK, in the laboratory of T. Michael Dexter, FRS. She conducted postdoctoral research at Harvard Medical School in the laboratory of T. Keith Blackwell, MD, PhD.  Barbra joined Amgen in 2001 to work on normal and malignant hematology initially and later expanded her focus to include immune-oncology with an emphasis on T-cell redirective therapies, specifically BiTE molecules. In 2013, she joined Pfizer to become involved with large molecule immuno-oncology including the Pfizer T-cell redirection programs and led diligence to look for a CAR T collaboration partner. This collaboration search resulted in the Cellectis partnership in 2014 and the collaboration with Servier for clinical execution of UCART19 and other preclinical assets.
    5 August 2021
    Interview
  • Enhancing preclinical predictivity: what is going wrong between preclinical in vitro/in vivo and clinical in vivo settings?

    C Schmees
    Christian Schmees, PhD
    Head of Tumor Biology, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Germany
    Christian Schmees is heading the Tumor Biology group at the Natural and Medical Sciences Institute (NMI) at the University of Tuebingen, Germany. He received his undergraduate degree in biochemistry from Tuebingen University in 2002. Since 2006 he holds a PhD (with highest honors) in cancer immunology from the Technical University of Munich, Germany. His thesis resulted in the identification of gamma-glutamyl-transpeptidase as the major factor for T cell specific immune evasion of the tumorigenic bacterium Helicobacter pylori. As a post-doc he joined the laboratories of Carl-Henrik Heldin at the Ludwig Institute for Cancer Research (LICR) in Uppsala, Sweden (2006-2010) and Philippe Bastiaens at the Max-Planck Institute of Molecular Physiology in Dortmund, Germany (2010-2011). He received fellowships from the German Research Foundation and the LICR to support his research on differential regulation of intracellular PDGF α- and β-receptor trafficking in cancer cells. In 2011 he joined the Natural and Medical Sciences Institute at the University of Tuebingen (NMI) as a senior scientist in tumor biology and was appointed Head of Tumor Biology in 2014. Ongoing projects in his group are focusing on the development of clinically relevant cellular model systems for drug development and target validation in translational oncology. These approaches are combined with gene editing and silencing technologies as well as protein profiling and immunophenotyping platforms for mode-of-action analyses of different compound classes. Dr. Schmees is member of the Association for Cancer Immunotherapy (CIMT).
    5 August 2021
    Foreword
  • Microphysiological systems for immuno-oncology: opportunities and challenges

    L Low
    Lucie A Low
    National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd, 9th Floor, Bethesda, MD 20892, USA lucie.low@nih.gov
    Lucie Low is the scientific program manager of the trans-NIH Tissue Chip for Drug Screening program at the National Center for Advancing Translational Sciences (NCATS). She also serves as the NIH-NASA liaison point of contact, facilitating collaborations between NIH and NASA on areas of overlapping agency interest. Prior to joining NCATS in 2016, Low was an intramural research fellow at the National Center for Complementary and Integrative Health (NCCIH), researching the complex interactions between pain, emotion and cognition. She obtained her undergraduate degree from Magdalen College, Oxford University, and her Masters and PhD degrees in Neuroscience from University College London in the UK. She undertook postdoctoral training at McGill University in Montreal, Canada, before joining the US National Institutes of Health in 2012. She has authored over 20 peer-reviewed manuscripts on the neuroscience of pain and tissue chips.
    5 August 2021
    Editorial
  • Advancement of precision oncology by integration of highly sensitive protein profiling technologies and patient-derived cell models for functional efficacy testing

    M Pawlak,
    Michael Pawlak
    Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany and Natural and Medical Sciences Institute Technologietransfer GmbH, Reutlingen, Germany
    M Templin,
    Markus Templin
    Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany
    C Schmees
    Christian Schmees
    Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany
    Christian Schmees is heading the Tumor Biology group at the Natural and Medical Sciences Institute (NMI) at the University of Tuebingen, Germany. He received his undergraduate degree in biochemistry from Tuebingen University in 2002. Since 2006 he holds a PhD (with highest honors) in cancer immunology from the Technical University of Munich, Germany. His thesis resulted in the identification of gamma-glutamyl-transpeptidase as the major factor for T cell specific immune evasion of the tumorigenic bacterium Helicobacter pylori. As a post-doc he joined the laboratories of Carl-Henrik Heldin at the Ludwig Institute for Cancer Research (LICR) in Uppsala, Sweden (2006-2010) and Philippe Bastiaens at the Max-Planck Institute of Molecular Physiology in Dortmund, Germany (2010-2011). He received fellowships from the German Research Foundation and the LICR to support his research on differential regulation of intracellular PDGF α- and β-receptor trafficking in cancer cells. In 2011 he joined the Natural and Medical Sciences Institute at the University of Tuebingen (NMI) as a senior scientist in tumor biology and was appointed Head of Tumor Biology in 2014. Ongoing projects in his group are focusing on the development of clinically relevant cellular model systems for drug development and target validation in translational oncology. These approaches are combined with gene editing and silencing technologies as well as protein profiling and immunophenotyping platforms for mode-of-action analyses of different compound classes. Dr. Schmees is member of the Association for Cancer Immunotherapy (CIMT).
    5 August 2021
    Expert Insight
  • Recent evolution in the bispecific antibody and engineered cytokine fields

    R Clynes
    Raphael Clynes
    Vice President of Translational Biology, Xencor
    Raphael Clynes, MD, PhD, Vice President of Translational Biology, Xencor. Dr. Clynes is a medical oncologist/hematolo-gist and a cellular immunologist with more than 100 publications in cancer and autoimmunity. Prior to joining Xencor in 2017, Dr. Clynes evaluated combination immunotherapies in Early Clinical Development at Bristol Myers Squibb. Prior to moving to industry in 2014, Dr. Clynes led NIH-funded research programs over two decades in cancer and autoimmunity at The Rockefeller University, MSKCC and Columbia University.
    5 August 2021
    Interview
  • Enhancing preclinical predictivity in I-O: what is going wrong between preclinical in vitro/in vivo and clinical settings?

    P Ellmark,
    Peter Ellmark
    Chief Scientific Officer, Alligator Bioscience
    Peter Ellmark joined Alligator Bioscience in 2008 and is Chief scientific officer since 2021. He holds a PhD and an associate professorship in Immunotechnology at Lund University and has more than 20 years’ experience of developing antibodies for immunotherapy of cancer. Dr. Ellmark´s research interest is focused on developing mono- and bispecific antibodies, in particular CD40 targeting therapies, for tumor directed immunotherapy of cancer.
    D Gilham,
    David Gilham
    Chief Scientific Officer, Celyad Oncology
    M Steegmaier et al.
    Martin Steegmaier
    Head of Research, MorphoSys
    5 August 2021
    Expert Roundtable
  • Enhancing preclinical predictivity in I-O: what is going wrong between preclinical in vitro/in vivo and clinical settings?

    P Ellmark,
    Peter Ellmark
    Chief Scientific Officer, Alligator Bioscience
    Peter Ellmark joined Alligator Bioscience in 2008 and is Chief scientific officer since 2021. He holds a PhD and an associate professorship in Immunotechnology at Lund University and has more than 20 years’ experience of developing antibodies for immunotherapy of cancer. Dr. Ellmark´s research interest is focused on developing mono- and bispecific antibodies, in particular CD40 targeting therapies, for tumor directed immunotherapy of cancer.
    D Gilham,
    David Gilham
    Chief Scientific Officer, Celyad Oncology
    M Steegmaier et al.
    Martin Steegmaier
    Head of Research, MorphoSys
    5 August 2021
    Expert Roundtable Video